Abstracts Archive - Page 394 of 2607 - ACR Meeting Abstracts

Abstract Number: 1468 • ACR Convergence 2023
Prediction of Cardiovascular Disease in Patients with Systemic Lupus Erythematosus Using a Machine Learning Algorithm for Time-to-Event Outcomes: Random Survival Forest
Hsin Yen Liu¹, Jiandong Su², Dennisse Bonilla², Sara Duaibes², Juan Pablo Diaz Martinez³ and Zahi Touma¹, ¹University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have higher risks of developing cardiovascular disease (CVD). Traditional risk factors do not adequately capture the risk of…
Abstract Number: 1477 • ACR Convergence 2023
Clinical and Economic Burden of Herpes Zoster in Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
Nikita Stempniewicz¹, Andrea Steffens², Kimvi Kim¹, Christopher Bell³, Mary DuCharme², Helen Trenz² and David Singer¹, ¹GlaxoSmithKline, Philadelphia, PA, ²Optum, Eden Prairie, MN, ³GlaxoSmithKline, US Value Evidence and Outcomes, Durham, NC
Background/Purpose: Herpes zoster (HZ) is characterized by a painful dermatomal rash and is associated with increased healthcare costs and reduced quality of life. Systemic lupus…
Abstract Number: 1479 • ACR Convergence 2023
Risk Factors for Human Papillomavirus Cervical Infection and Clearance in Patients with Systemic Lupus Erythematosus: The PAPILUP Study
Tiphaine Goulenok¹, Valentine Marie Ferre², Celine Mendes¹, Lea Dayan³, Margot Bucau¹, Fatima Farhi¹, Thomas Papo² and Karim Sacre², ¹Assistance Publique Hopitaux de Paris, Paris, France, ²Université Paris Cité, Paris, France, ³Maison de Sante les Epinettes, Paris, France
Background/Purpose: An impaired clearance of cervical human papillomavirus (HPV) related to inadequate immune responses may result in persistent infection and increase the risk to develop…
Abstract Number: 1469 • ACR Convergence 2023
Prevalence of Cardiovascular Disease in a Populations Based Registry of Patients with Systemic Lupus Erythematosus
Daniel Joyce¹, Jeffrey. Berger², Allison Guttmann³, Ghadeer Hasan⁴, Jill Buyon⁵, H Michael Belmont¹, Jane Salmon⁶, Anca Askanase⁷, Joan Bathon⁸, Laura Geraldino-Pardilla⁹, Yousaf Ali¹⁰, Ellen Ginzler¹¹, Chaim Putterman¹², Caroline Gordon¹³, Charles Helmick¹⁴, Kamil Barbour¹⁵, Heather Gold¹⁶, Hilary Parton¹⁷ and Peter Izmirly², ¹NYU School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³Atlantic Health System, Summit, NJ, ⁴Optum, Jersey City, NJ, ⁵NYU Grossman School of Medicine, New York, NY, ⁶Hospital for Special Surgery, New York, NY, ⁷Columbia University Medical Center, New York, NY, ⁸Columbia University, New York, NY, ⁹Division of Rheumatology, Columbia University Irving Medical Center, New York, NY, ¹⁰Icahn School of Medicine at Mount Sinai, New York, NY, ¹¹SUNY Downstate Health Sciences University, Brooklyn, NY, ¹²Albert Einstein College of Medicine, Bronx, NY, ¹³Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ¹⁴NA, Atlanta, GA, ¹⁵Centers for Disease Control and Prevention, Atlanta, GA, ¹⁶New York University, New York, NY, ¹⁷New York City Department of Health and Mental Hygiene, Queens, NY
Background/Purpose: Patients with SLE are at increased risk for cardiovascular disease (CVD). Population estimates of CVD in SLE remains limited for non-White racial/ethnic populations in…
Abstract Number: 1484 • ACR Convergence 2023
Ruminococcus Implicated in the Clinical Development of Lupus Nephritis: A Systematic Review of the Literature
Katarzyna Karpinska-Leydier¹, Arseni Khorochkov², Ambar Morales-Rodriguez¹, Nur Barlas¹, Sait Barlas¹, Abraham Bell¹, Magdy El-Din³ and Shristi Basnyat⁴, ¹Florida State University - Cape Coral Hospital, Cape Coral, FL, ²Poznan University of Medical Sciences, Poznań, Poland, ³Florida State University/Lee physicians group, Cape Coral, FL, ⁴Florida State University/Lee physicians group, Fort Myers, FL
Background/Purpose: Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE). Current investigations implicate microbiome changes in disease pathogenesis, particularly pathobiont expansions of…
Abstract Number: 1454 • ACR Convergence 2023
Neuropsychiatric Systemic Lupus Erythematosus in Children: A Scoping Review
Alexandra Theisen¹, Ekemini Ogbu², Emily Beil³, Onengiya Harry⁴, Simone Appenzeller⁵, Ryan Kammeyer⁶, Hanne Van der Heijen⁷, Andrea Knight⁸, Hannah Craven⁹ and Martha Rodriguez¹⁰, ¹Saint Louis University School of Medicine, SSM Health Cardinal Glennon Children's Hospital, St. Louis, MO, ²Cincinnati Children's Hospital Medical Center, University of Cincinnati School of Medicine, Johns Hopkins University, Cincinnati, OH, ³Baylor College of Medicine / Texas Children's Hospital, Houston, TX, ⁴Brenner Children's Hospital - Wake Forest Baptist Health, Winston-Salem, NC, ⁵UNICAMP, Campinas, Brazil, ⁶University of Colorado School of Medicine, Children's Hospital Colorado, Denver, CO, ⁷Boston Children's Hospital, Harvard Medical School, Boston, MA, ⁸The Hospital for Sick Children, Toronto, ON, Canada, ⁹Ruth Lilly Medical Library, Indiana University School of Medicine, Indianapolis, IN, ¹⁰Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) remains a challenging entity to diagnose and treat. The clinical heterogeneity of NPSLE coupled with the difficulty with attribution…
Abstract Number: 1460 • ACR Convergence 2023
Impact of Neuropsychiatric Involvement on Health-related Quality of Life in Patients with Systemic Lupus Erythematosus
Dionysis Nikolopoulos¹, Nursen Cetrez², Julius Lindblom² and Ioannis Parodis², ¹Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Substantial proportions of systemic lupus erythematosus (SLE) patients report severe fatigue and adverse Health-related Quality of Life (HRQoL). Particularly neuropsychiatric manifestations have been associated…
Abstract Number: 1483 • ACR Convergence 2023
High Chronicity Index of the Modified NIH (National Institute of Health) Scoring System of Lupus Nephritis Is Associated with Increased Risk of End-stage Kidney Disease: A Retrospective Single-center Study
Shiori Nakagawa, Yasunori Iwata, Takahiro Yuasa, Keisuke Sako, Keisuke Horikoshi, Taichiro Minami, Megumi Oshima, Tadashi Toyama, Shinji Kitajima, Akinori Hara, Norihiko Sakai, Miho Shimizu and Takashi Wada, Department of Nephrology, Kanazawa University Hospital, Kanazawa, Japan
Background/Purpose: Lupus nephritis (LN) is a major manifestation which develops in more than 50% of patients with systemic lupus erythematosus (SLE), and is also a…
Abstract Number: 1391 • ACR Convergence 2023
Rates of Remission in Patients with Axial Spondyloarthritis Treated in Tertiary Care
Franziska Neinert¹, Imke Redeker², Styliani Tsiami¹, David Kiefer¹, Barbara Guminski¹, Xenofon Baraliakos³, Juergen Braun¹ and Uta Kiltz⁴, ¹Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany, ²Ruhr Universität Bochum, Bochum, Germany, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Achieving remission is the treatment target for patients (pts.) with axial spondyloarthritis (axSpA).Remission rates over longer periods in a real-life setting have not been…
Abstract Number: 1482 • ACR Convergence 2023
Change in the SLE Mortality Rate and Prevalence of Lupus Nephritis Overtime: Single Center Retrospective Study in Japan
Takehiro Nakai¹, Sho Fukui², Takahiro Asano¹, Futoshi Iwata¹, Hiroki Ozawa³, Satoshi Kawaai¹, Yukihiko Ikeda⁴, Haruyuki Yanaoka¹, Hiromichi Tamaki¹, Mitsumasa Kishimoto⁵, Kenichi YAMAGUCHI⁶ and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²Brigham and Women's Hospital, Boston, MA, ³Immuno-Rheumatology Center, St.Luke's International Hospital, Tokyo, Japan, ⁴St Luke's international hospital in Japan, Tokyo, Japan, ⁵Kyorin University School of Medicine, Yokohoma, Japan, ⁶St.Luke's International Hospital, Tokyo, Japan
Background/Purpose: Over the past several decades, the treatment of lupus has seen significant advancements, with the approval of belimumab in 2017, and anifrolumab in 2021.…
Abstract Number: 1450 • ACR Convergence 2023
Clinical Manifestations and Outcomes in Systemic Lupus Erythematosus Patients Who Received Antiviral Therapy During the COVID-19 Omicron Variant Wave: Results from a Single Center Cohort of Puerto Rico
Lilliana Serrano-Arroyo¹, Rafael Ríos-Rivera², Ariana González-Meléndez² and Luis M. Vilá², ¹Centro Medico Episcopal San Lucas, San Juan, PR, ²University of Puerto Rico Medical Sciences Campus, San Juan, PR
Background/Purpose: The impact of COVID-19 in patients with systemic lupus erythematosus (SLE) has been a subject of great concern. Antiviral therapy has emerged as a…
Abstract Number: 1397 • ACR Convergence 2023
Sustainability of Clinical Response at Week 52 to Upadacitinib Among Patients with Axial SpA: Data from the SELECT-AXIS 1 and SELECT-AXIS 2 Trials
Victoria Navarro-Compán¹, Lianne Gensler², Martin Rudwaleit³, Fabiana Ganz⁴, Shirley Chen⁴, Jayne Stigler⁴, Anna Schmagel⁴ and Xenofon Baraliakos⁵, ¹Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ²University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, ³University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ⁴AbbVie, Inc., North Chicago, IL, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Bochum, Germany
Background/Purpose: Upadacitinib 15 mg (UPA), an oral Janus kinase inhibitor, has shown efficacy and tolerability through 14 weeks in patients (pts) with active radiographic axial…
Abstract Number: 1141 • ACR Convergence 2023
COVID-19 Vaccination Status and Adverse Events Following SARS-CoV-2 Vaccine in Autoimmune Inflammatory Rheumatic Disease (AIRD) Patients: A Single Center Experience
Vincent Luceño¹, Peter Paolo Daleon¹ and Sandra Navarra², ¹University of Santo Tomas Hospital, City of Manila, Philippines, ²University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines
Background/Purpose: Autoimmune inflammatory rheumatic diseases (AIRD) were associated with an increased risk for COVID-19 infection, worse clinical outcomes, and COVID-19- related deaths. Vaccines carry the…
Abstract Number: 1390 • ACR Convergence 2023
Prediction of Low Disease Activity in Patients with Ankylosing Spondylitis Treated with Secukinumab in Real World – Data from a German Observational Study
Asmir Vodencarevic¹, Jan Brandt-Juergens², Daniel Peterlik¹, Benjamin Gmeiner¹ and Uta Kiltz³, ¹Novartis Pharma GmbH, Nürnberg, Germany, ²rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Secukinumab (SEC) proved to be an effective treatment for patients suffering from ankylosing spondylitis (AS) in randomized clinical trials [1]. There is only limited…
Abstract Number: 1140 • ACR Convergence 2023
Inflammation Is More Prominent Than Joint Damage at Initial Visits of Patients with Inflammatory Arthritides, but Organ Damage Is More Prominent and Patient Distress Is as Prominent as Inflammation in Overall Rheumatology Care: Data from a Feasible Physician RheuMetric Checklist
Theodore Pincus¹, Tengfei Li² and Juan Schmukler¹, ¹Rush University Medical Center, Chicago, IL, ²Georgetown University, Washington, DC
Background/Purpose: Patients consult rheumatologists for symptoms which may result from inflammatory activity or reversible problems (INF), joint or other organ damage or irreversible problems (DAM),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].